Donor-derived cell-free DNA and its utility in kidney transplantation: A myth or a reality

Table 2 Summaries of studies of Allosure, Prospera, Viracor TRAC, and their diagnostic abilities

Ref.	Journal/year	Assay used	SNPs	Limit of quantification	Limit of detection	Sensitivity	Specificity	Area under curve	Coefficient of variation
Grskovic et al[48]	J Mol Diagn/2016	Allosure	266	0.2%	0.16%	0.83	0.84		7.7% (dd-cfDNA < 2%). 4.5% (dd-cfDNA ≥ 2%)
Bloom et al[13]	J Am Soc Nephrol/2017	Allosure	266			0.59	0.85	0.74
Jordan et al[49]	Transplant Direct/2018	Allosure	266	0.2%-16%				0.86
Sigdel et al[14]	J Clin Med/2018	Prospera	13392			0.887	0.726	0.87 (87%)
Altuğ et al[50]	Transplantation/2019	Prospera	13962	0.15% (related donors); 0.23% (unrelated donor)	0.15% (related donors); 0.23% (unrelated donor)				4.29%
Melancon et al[51]	Kidney360/2020	Allosure vs Prospera	266 vs 13392			0.45 vs 0.55	0.85 vs 0.69	0.73 (73%) vs 75 0.75 (75%)
	Viracor TRAC	Quantitative PCR	0.5%-60%		0.579		0.853

dd-cfDNA: Donor-derived cell-free DNA; SNP: Single nucleotide polymorphism.